NPDT Evaluation in Children With CFTR and (PSC)
The investigators hypothesize that PSC in children is associated with mutations and functional changes of the cystic fibrosis (CF) gene.
Primary Sclerosing Cholangitis
Inflammatory Bowel Disease
Procedure: nasal potential difference testing
|Official Title:||Nasal Potential Difference Testing: Evaluation of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Function in Children With Primary Sclerosing Cholangitis (PSC)|
- CFTR DNA analysis
- Nasal potential difference testing
- Sweat test
|Study Start Date:||January 2004|
|Estimated Primary Completion Date:||January 2006 (Final data collection date for primary outcome measure)|
The purpose of this protocol is to perform Nasal Transepithelial Potential Difference (NTPD) testing to assess the function of the cystic fibrosis gene product, a chloride channel referred to as CFTR, in patients diagnosed with PSC and/or inflammatory bowel disease in childhood and currently 12 years of age and greater.
Dr. Freedman's laboratory has shown that there is an increased prevalence of CFTR abnormalities in adults with PSC as demonstrated by genotype and phenotype analysis. We hypothesize that abnormalities in CFTR based on exhaustive genotype and phenotype assessments are associated with the presence of PSC in children. We would like to enroll patients with inflammatory bowel disease and no PSC to use as a "control group".
Subjects with PSC and/or inflammatory bowel disease diagnosed in childhood, currently aged 12 years and above, will be enrolled in study protocols at Children's Hospital in Boston, which will have received their local IRB approval. The only role for BIDMC will be to perform NTPD testing on these subjects. No other assessment or testing will be performed at our site. We will not be involved in any other aspect of care for these subjects.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00179439
|United States, Massachusetts|
|Beth Israel Deaconess Medical Center|
|Boston, Massachusetts, United States, 02215|
|Study Director:||Harpreet Pall, MD||Children's Hospital Boston|
|Principal Investigator:||Steven D Freedman, MD, PhD||Beth Israel Deaconess Medical Center|